NEWS & INSIGHTS /

Nicolas Wolikow, on mission at Cure51

Inside Cure51

Publication Date:
TO READ NEXT

“A super survivor”: British woman beats cancer.

"Co-founder of this start-up, created at the end of 2022, Nicolas Wolikow wants to fight cancer. How? By identifying the biological mechanisms shared by the few thousand survivors who were initially thought to be doomed."

Read more

Table of Contents
in THIS ARTICLE
In this article

NICOLAS WOLIKOW

Co-Founder CEO

MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES
yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

until-all-survive-website-for-cancer-patients

UntilAllSurvive.com: we're launching a new website for cancer patients!

until-all-survive-website-for-cancer-patients

UntilAllSurvive.com: we're launching a new website for cancer patients!

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

READ MORE

MORE TOP STORIES
marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

precision-medicine-nicolas-wolikow

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

We’re thrilled to announce a major milestone for Cure51: a strategic collaboration with Servier to uncover new therapeutic targets in glioblastoma

READ MORE

MORE TOP STORIES

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

Building a Product Ecosystem for Cancer Target Discovery

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

CHUV Lausanne received their Rosalind trophy!

CHUV-Centre-hospitalier-universitaire-vaudois

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

precision-medicine-nicolas-wolikow

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Global-Cancer-Research-Compliance

NEWS & INSIGHTS

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

Contact us

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

Follow us

Linkedin

Facebook

Instagram

Contact us

Contact us

Follow us

Linkedin

Facebook

Instagram

Contact us

ROSALIND

Contact us